| 000 | 01804 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514080151.0 | ||
| 264 | 0 | _c20040520 | |
| 008 | 200405s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/sj.bmt.1704190 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShapira, M Y | |
| 245 | 0 | 0 |
_aA new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cSep 2003 |
||
| 300 |
_a557-61 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBusulfan _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclosporine _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xdrug therapy |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Mobilization |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xmortality |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xmethods |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 700 | 1 | _aOr, R | |
| 700 | 1 | _aResnick, I B | |
| 700 | 1 | _aBitan, M | |
| 700 | 1 | _aAckerstein, A | |
| 700 | 1 | _aSamuel, S | |
| 700 | 1 | _aElad, S | |
| 700 | 1 | _aZilberman, I | |
| 700 | 1 | _aMiron, S | |
| 700 | 1 | _aSlavin, S | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 32 _gno. 6 _gp. 557-61 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bmt.1704190 _zAvailable from publisher's website |
| 999 |
_c12722559 _d12722559 |
||